Definitions |
![]() | 2 |
Definitions |
![]() | 3 |
Definitions |
![]() | 4 |
Definitions |
![]() | 5 |
Reconciliations |
In thousands, except for per share data |
Funds From Operations | ||||
Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Net income (loss) applicable to common shares | $ | 43,200 | $ | 829,325 | $ | 43,987 | $ | 1,058,424 | |||||||
Real estate related depreciation and amortization | 190,798 | 130,759 | 659,989 | 549,499 | |||||||||||
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures | 15,151 | 15,237 | 60,303 | 63,967 | |||||||||||
Noncontrolling interests' share of real estate related depreciation and amortization | (5,128 | ) | (3,828 | ) | (20,054 | ) | (11,795 | ) | |||||||
Other real estate-related depreciation and amortization | 1,357 | 2,071 | 6,155 | 6,977 | |||||||||||
Loss (gain) on sales of real estate, net | (4,193 | ) | (763,774 | ) | (22,900 | ) | (925,985 | ) | |||||||
Healthpeak's share of loss (gain) on sales of real estate, net, from unconsolidated joint ventures | (2,118 | ) | — | (2,118 | ) | — | |||||||||
Noncontrolling interests' share of gain (loss) on sales of real estate, net | 129 | — | 335 | — | |||||||||||
Loss (gain) upon change of control, net(1) | (155,225 | ) | (50,171 | ) | (166,707 | ) | (9,154 | ) | |||||||
Taxes associated with real estate dispositions | — | 2,765 | — | 3,913 | |||||||||||
Impairments (recoveries) of depreciable real estate, net(2) | 110,284 | 32,803 | 221,317 | 44,343 | |||||||||||
NAREIT FFO applicable to common shares | 194,255 | 195,187 | 780,307 | 780,189 | |||||||||||
Distributions on dilutive convertible units and other | 1,637 | — | 6,592 | — | |||||||||||
Diluted NAREIT FFO applicable to common shares | $ | 195,892 | $ | 195,187 | $ | 786,899 | $ | 780,189 | |||||||
Weighted average shares outstanding - diluted NAREIT FFO | 506,017 | 473,289 | 494,335 | 470,719 | |||||||||||
Impact of adjustments to NAREIT FFO: | |||||||||||||||
Transaction-related items | $ | 1,688 | $ | 2,416 | $ | 15,347 | $ | 11,029 | |||||||
Other impairments (recoveries) and losses (gains), net(3) | — | 3,277 | 10,147 | 7,619 | |||||||||||
Severance and related charges(4) | — | 595 | 5,063 | 13,906 | |||||||||||
Loss on debt extinguishments(5) | 22,213 | 263 | 58,364 | 44,162 | |||||||||||
Litigation costs (recoveries) | 29 | 323 | (520 | ) | 363 | ||||||||||
Casualty-related charges (recoveries), net(6) | 530 | — | (4,106 | ) | — | ||||||||||
Foreign currency remeasurement losses (gains) | 100 | 72 | (250 | ) | (35 | ) | |||||||||
Total adjustments | 24,560 | 6,946 | 84,045 | 77,044 | |||||||||||
FFO as Adjusted applicable to common shares | 218,815 | 202,133 | 864,352 | 857,233 | |||||||||||
Distributions on dilutive convertible units and other | 1,585 | (18 | ) | 6,396 | (198 | ) | |||||||||
Diluted FFO as Adjusted applicable to common shares | $ | 220,400 | $ | 202,115 | $ | 870,748 | $ | 857,035 | |||||||
Weighted average shares outstanding - diluted FFO as Adjusted | 506,017 | 473,289 | 494,335 | 470,719 | |||||||||||
Diluted earnings per common share | $ | 0.09 | $ | 1.73 | $ | 0.09 | $ | 2.24 | |||||||
Depreciation and amortization | 0.40 | 0.31 | 1.43 | 1.30 | |||||||||||
Loss (gain) on sales of real estate, net | (0.01 | ) | (1.61 | ) | (0.04 | ) | (1.96 | ) | |||||||
Loss (gain) upon change of control, net(1) | (0.31 | ) | (0.10 | ) | (0.34 | ) | (0.02 | ) | |||||||
Taxes associated with real estate dispositions | — | 0.01 | — | 0.01 | |||||||||||
Impairments (recoveries) of depreciable real estate, net(2) | 0.22 | 0.07 | 0.45 | 0.09 | |||||||||||
Diluted NAREIT FFO per common share | $ | 0.39 | $ | 0.41 | $ | 1.59 | $ | 1.66 | |||||||
Transaction-related items | — | 0.01 | 0.03 | 0.02 | |||||||||||
Other impairments (recoveries) and losses (gains), net(3) | — | 0.01 | 0.02 | 0.02 | |||||||||||
Severance and related charges(4) | — | — | 0.01 | 0.03 | |||||||||||
Loss on debt extinguishments(5) | 0.05 | — | 0.12 | 0.09 | |||||||||||
Casualty-related charges (recoveries), net(6) | — | — | (0.01 | ) | — | ||||||||||
Diluted FFO as Adjusted per common share | $ | 0.44 | $ | 0.43 | $ | 1.76 | $ | 1.82 | |||||||
![]() | 6 |
Reconciliations |
In thousands |
Funds Available for Distribution | ||||
Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
FFO as Adjusted applicable to common shares | $ | 218,815 | $ | 202,133 | $ | 864,352 | $ | 857,233 | |||||||
Amortization of deferred compensation(7) | 3,177 | 3,465 | 14,790 | 14,714 | |||||||||||
Amortization of deferred financing costs | 2,689 | 2,851 | 10,863 | 12,612 | |||||||||||
Straight-line rents | (6,259 | ) | (2,251 | ) | (28,451 | ) | (23,138 | ) | |||||||
FAD capital expenditures | (46,004 | ) | (35,956 | ) | (108,844 | ) | (106,193 | ) | |||||||
Lease restructure payments | 284 | 294 | 1,153 | 1,195 | |||||||||||
CCRC entrance fees(8) | 4,785 | 4,677 | 18,856 | 17,880 | |||||||||||
Deferred income taxes | (4,909 | ) | (5,993 | ) | (18,972 | ) | (18,744 | ) | |||||||
Other FAD adjustments(9) | (3,574 | ) | (1,219 | ) | (7,927 | ) | (9,162 | ) | |||||||
FAD applicable to common shares | 169,004 | 168,001 | 745,820 | 746,397 | |||||||||||
Distributions on dilutive convertible units and other | 1,637 | — | 6,591 | — | |||||||||||
Diluted FAD applicable to common shares | $ | 170,641 | $ | 168,001 | $ | 752,411 | $ | 746,397 | |||||||
Weighted average shares outstanding - diluted FAD | 506,017 | 473,289 | 494,335 | 470,719 | |||||||||||
(1) | For the three months ended December 31, 2019, primarily relates to the gain related to the deconsolidation of 19 previously consolidated senior housing assets that were contributed into a new unconsolidated joint venture (Sovereign Wealth Fund Senior Housing JV). For the year ended December 31, 2019, also includes the gain related to the acquisition of the outstanding equity interests in a previously unconsolidated senior housing joint venture (Vintage Park). For the three months ended December 31, 2018, represents the gain related to the acquisition of our partner's interests in four previously unconsolidated life science assets. For the year ended December 31, 2018, also includes the loss on consolidation of seven U.K. care homes. |
(2) | For the year ended December 31, 2019, includes a $6 million impairment charge related to depreciable real estate held by the CCRC JV, which we recognized in equity income (loss) from unconsolidated joint ventures in the consolidated statement of operations. |
(3) | For the year ended December 31, 2019, represents the impairment of 13 senior housing triple-net facilities under direct financing leases recognized as a result of entering into sales agreements. For the year ended December 31, 2018, represents the impairment of an undeveloped life science land parcel classified as held for sale, partially offset by an impairment recovery upon the sale of a mezzanine loan investment in March 2018. |
(4) | For the year ended December 31, 2018, primarily relates to the departure of our former Executive Chairman and corporate restructuring activities. |
(5) | For all periods presented, represents the premium associated with the prepayment of senior unsecured notes. |
(6) | For the three months ended December 31, 2019, represents evacuation costs related to hurricanes. The year ended December 31, 2019 also includes incremental insurance proceeds related to hurricanes in 2017. |
(7) | Excludes amounts related to the acceleration of deferred compensation for restricted stock units that vested upon the departure of certain former employees, which have already been excluded from FFO as Adjusted in severance and related charges. |
(8) | Represents our 49% share of our CCRC JV's non-refundable entrance fees collected in excess of amortization. |
(9) | Primarily includes our share of FAD capital expenditures from unconsolidated joint ventures, partially offset by noncontrolling interests' share of FAD capital expenditures from consolidated joint ventures. |
![]() | 7 |
Reconciliations |
In thousands |
Share of Unconsolidated Joint Venture NAREIT FFO, and FAD |
Three Months Ended December 31, 2019 | ||||||||||||||||||||||||||||
Total | CCRC JV | Other SHOP JVs | Senior Housing JV | U.K. JV | Medical Office | Remaining | ||||||||||||||||||||||
Equity income (loss) from unconsolidated joint ventures | $ | 1,387 | $ | (2,456 | ) | $ | (462 | ) | $ | 930 | $ | 871 | $ | 215 | $ | 2,289 | ||||||||||||
Real estate related depreciation and amortization | 15,151 | 12,073 | 947 | 150 | 1,733 | 200 | 48 | |||||||||||||||||||||
Loss (gain) on sales of real estate, net | (2,118 | ) | — | — | — | — | — | (2,118 | ) | |||||||||||||||||||
NAREIT FFO | $ | 14,420 | $ | 9,617 | $ | 485 | $ | 1,080 | $ | 2,604 | $ | 415 | $ | 219 | ||||||||||||||
FAD adjustments | 485 | 939 | (116 | ) | (34 | ) | (288 | ) | (25 | ) | 9 | |||||||||||||||||
FAD | $ | 14,905 | $ | 10,556 | $ | 369 | $ | 1,046 | $ | 2,316 | $ | 390 | $ | 228 | ||||||||||||||
![]() | 8 |
Reconciliations |
In thousands, except for per share data |
Projected Future Operations(1) | ||||
Full Year 2020 | |||||||
Low | High | ||||||
Diluted earnings per common share | $ | 0.70 | $ | 0.76 | |||
Real estate related depreciation and amortization | 1.40 | 1.40 | |||||
Real estate related depreciation and amortization on unconsolidated joint ventures | 0.20 | 0.20 | |||||
Real estate related depreciation and amortization on noncontrolling interests and other | (0.03 | ) | (0.03 | ) | |||
Loss (gain) on sales of real estate, net | (0.40 | ) | (0.40 | ) | |||
Loss (gain) upon consolidation of real estate, net | (0.24 | ) | (0.24 | ) | |||
Taxes associated with real estate disposition | 0.01 | 0.01 | |||||
Diluted NAREIT FFO per common share | $ | 1.64 | $ | 1.70 | |||
Transaction-related items | 0.21 | 0.21 | |||||
Other impairments (recoveries), net | (0.08 | ) | (0.08 | ) | |||
Diluted FFO as Adjusted per common share | $ | 1.77 | $ | 1.83 | |||
(1) | The foregoing projections reflect management’s view of current and future market conditions as of February 11, 2020 including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in our earnings press release for the quarter ended December 31, 2019 that was issued on February 11, 2020. However, these projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or larger than expected litigation settlements and expenses related to existing or future litigation matters. Our actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of February 11, 2020. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments. |
Share of Unconsolidated Joint Venture NAREIT FFO and Cash NOI |
Full Year 2020 | ||||||||
Low | High | |||||||
Equity income (loss) from unconsolidated joint ventures | $ | (72,000 | ) | $ | (68,000 | ) | ||
Real estate related depreciation and amortization | 103,000 | 107,000 | ||||||
NAREIT FFO | $ | 31,000 | $ | 39,000 | ||||
Adjustments to NAREIT FFO(1) | 3,500 | 3,500 | ||||||
Total NOI | $ | 34,500 | $ | 42,500 | ||||
Non-cash adjustments to NOI | (500 | ) | (500 | ) | ||||
Total Cash NOI | $ | 34,000 | $ | 42,000 | ||||
(1) | Includes interest and general and administrative expenses. |
![]() | 9 |
Reconciliations |
In millions |
Projected SPP Cash NOI(1)(2) |
Senior Housing(3) | Life Science | Medical Office | Other | Total | |||||||||||||||
Cash NOI(4) | $ | 399 | $ | 389 | $ | 344 | $ | 44 | $ | 1,177 | |||||||||
Interest income | — | — | — | 15 | 15 | ||||||||||||||
Cash NOI plus interest income | 399 | 389 | 344 | 59 | 1,191 | ||||||||||||||
Interest income | — | — | — | (15 | ) | (15 | ) | ||||||||||||
Non-cash adjustments to cash NOI(5) | 2 | 27 | 7 | (2 | ) | 33 | |||||||||||||
NOI | 400 | 416 | 351 | 42 | 1,210 | ||||||||||||||
Non-SPP NOI | (242 | ) | (155 | ) | (43 | ) | (1 | ) | (441 | ) | |||||||||
SPP NOI | 158 | 261 | 309 | 41 | 769 | ||||||||||||||
Non-cash adjustments to SPP NOI(5) | (2 | ) | (7 | ) | (7 | ) | 2 | (13 | ) | ||||||||||
SPP cash NOI | $ | 156 | $ | 254 | $ | 302 | $ | 43 | 755 | ||||||||||
Addback adjustments(6) | 455 | ||||||||||||||||||
Other income and expenses(7) | 357 | ||||||||||||||||||
Costs and expenses(8) | (1,182 | ) | |||||||||||||||||
Other impairments (recoveries), net | — | ||||||||||||||||||
Net income (loss) | $ | 385 | |||||||||||||||||
Senior Housing(3) | Life Science | Medical Office | Other | Total | |||||||||||||||
Cash NOI(4) | $ | 411 | $ | 392 | $ | 348 | $ | 45 | $ | 1,195 | |||||||||
Interest income | — | — | — | 15 | 15 | ||||||||||||||
Cash NOI plus interest income | 411 | 392 | 348 | 59 | 1,210 | ||||||||||||||
Interest income | — | — | — | (15 | ) | (15 | ) | ||||||||||||
Non-cash adjustments to cash NOI(5) | 1 | 27 | 7 | (2 | ) | 33 | |||||||||||||
NOI | 412 | 419 | 355 | 42 | 1,228 | ||||||||||||||
Non-SPP NOI | (251 | ) | (156 | ) | (43 | ) | (1 | ) | (452 | ) | |||||||||
SPP NOI | 161 | 263 | 312 | 41 | 776 | ||||||||||||||
Non-cash adjustments to SPP NOI(5) | (2 | ) | (7 | ) | (7 | ) | 2 | (13 | ) | ||||||||||
SPP cash NOI | $ | 159 | $ | 256 | $ | 305 | $ | 43 | 763 | ||||||||||
Addback adjustments(6) | 465 | ||||||||||||||||||
Other income and expenses(7) | 362 | ||||||||||||||||||
Costs and expenses(8) | (1,177 | ) | |||||||||||||||||
Other impairments (recoveries), net | — | ||||||||||||||||||
Net income (loss) | $ | 412 | |||||||||||||||||
![]() | 10 |
Reconciliations |
In millions |
Senior Housing(3) | Life Science | Medical Office | Other | Total | |||||||||||||||
Cash NOI(4) | $ | 423 | $ | 311 | $ | 342 | $ | 53 | $ | 1,129 | |||||||||
Interest income | 10 | 10 | |||||||||||||||||
Cash NOI plus interest income | 423 | 311 | 342 | 63 | 1,139 | ||||||||||||||
Interest income | (10 | ) | (10 | ) | |||||||||||||||
Non-cash adjustments to cash NOI(5) | (23 | ) | 22 | 6 | (1 | ) | 4 | ||||||||||||
NOI | 400 | 333 | 348 | 51 | 1,133 | ||||||||||||||
Non-SPP NOI | (241 | ) | (83 | ) | (44 | ) | (11 | ) | (379 | ) | |||||||||
SPP NOI | 159 | 250 | 304 | 41 | 754 | ||||||||||||||
Non-cash adjustments to SPP NOI(5) | (2 | ) | (6 | ) | (7 | ) | 1 | (13 | ) | ||||||||||
SPP cash NOI | $ | 157 | $ | 244 | $ | 297 | $ | 42 | 741 | ||||||||||
Addback adjustments(6) | 392 | ||||||||||||||||||
Other income and expenses(7) | 199 | ||||||||||||||||||
Costs and expenses(8) | (1,046 | ) | |||||||||||||||||
Other impairments (recoveries), net | (226 | ) | |||||||||||||||||
Net income (loss) | $ | 60 | |||||||||||||||||
Senior Housing(3) | Life Science | Medical Office | Other | Total | |||||
Low | (1.00%) | 4.00% | 1.75% | 1.75% | 2.00% | ||||
High | 1.00% | 5.00% | 2.75% | 2.50% | 3.00% | ||||
(1) | The foregoing projections reflect management’s view of current and future market conditions as of February 11, 2020 including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in our earnings press release for the quarter ended December 31, 2019 that was issued on February 11, 2020. However, these projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or larger than expected litigation settlements and expenses related to existing or future litigation matters. Our actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of February 11, 2020. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments. |
(2) | Does not foot due to rounding and adjustments made to SPP high and low ranges reported by segment. |
(3) | Includes senior housing triple-net and SHOP. |
(4) | Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses, including our share of our joint ventures. |
(5) | Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, the deferral of community fees, net of amortization, management contract termination expense, actuarial reserves for insurance claims that have been incurred but not reported, and lease termination fees. |
(6) | Represents non-SPP NOI and non-cash adjustments to SPP NOI. |
(7) | Represents interest income, gain (loss) on sales of real estate, net, other income (expense), net, income taxes benefit (expense), and equity income (loss) from unconsolidated joint ventures, excluding NOI. |
(8) | Represents interest expense, depreciation and amortization, general and administrative, transaction costs, and loss on debt extinguishments. |
![]() | 11 |
Reconciliations |
In thousands |
Enterprise Gross Assets and Portfolio Investment |
December 31, 2019 | |||||||||||||||||||||||||||
Senior Housing Triple-net | SHOP | Life Science | Medical Office | Other | Corporate Non-segment | Total | |||||||||||||||||||||
Consolidated total assets | $ | 1,081,486 | $ | 2,841,730 | $ | 5,117,051 | $ | 3,615,493 | $ | 1,248,701 | $ | 128,430 | $ | 14,032,891 | |||||||||||||
Investments in and advances to unconsolidated JVs | — | — | — | — | (825,515 | ) | — | (825,515 | ) | ||||||||||||||||||
Accumulated depreciation and amortization | 438,593 | 632,206 | 822,393 | 1,329,661 | 96,544 | — | 3,319,397 | ||||||||||||||||||||
Consolidated Gross Assets | $ | 1,520,079 | $ | 3,473,936 | $ | 5,939,444 | $ | 4,945,154 | $ | 519,730 | $ | 128,430 | $ | 16,526,773 | |||||||||||||
Share of unconsolidated JV gross assets | — | — | — | — | 1,617,062 | — | 1,617,062 | ||||||||||||||||||||
Enterprise Gross Assets | $ | 1,520,079 | $ | 3,473,936 | $ | 5,939,444 | $ | 4,945,154 | $ | 2,136,792 | $ | 128,430 | $ | 18,143,835 | |||||||||||||
Land held for development | — | — | (96,882 | ) | (9,458 | ) | — | — | (106,340 | ) | |||||||||||||||||
Fully depreciated real estate and intangibles | 54,646 | 94,619 | 339,814 | 439,634 | 9,181 | — | 937,894 | ||||||||||||||||||||
Non-real estate related assets(1) | (118,947 | ) | (202,861 | ) | (230,086 | ) | (298,525 | ) | (277,556 | ) | (128,430 | ) | (1,256,405 | ) | |||||||||||||
Real estate intangible liabilities | (18,709 | ) | (8,599 | ) | (96,494 | ) | (89,952 | ) | (4,871 | ) | — | (218,625 | ) | ||||||||||||||
Portfolio Investment | $ | 1,437,069 | $ | 3,357,095 | $ | 5,855,796 | $ | 4,986,853 | $ | 1,863,546 | $ | — | $ | 17,500,359 | |||||||||||||
Investment by Type: | |||||||||||||||||||||||||||
Wholly-owned | $ | 1,437,069 | $ | 3,357,095 | $ | 5,855,796 | $ | 4,986,853 | $ | 504,794 | $ | — | $ | 16,141,607 | |||||||||||||
Share of unconsolidated JVs | — | — | — | — | 1,358,752 | — | 1,358,752 | ||||||||||||||||||||
Portfolio Investment | $ | 1,437,069 | $ | 3,357,095 | $ | 5,855,796 | $ | 4,986,853 | $ | 1,863,546 | $ | — | $ | 17,500,359 | |||||||||||||
(1) | Includes straight-line rent payables and receivables, net of reserves; lease commissions - 2nd generation, net of amortization; cash and restricted cash; our share of the value attributable to refundable Entrance Fee liabilities for the CCRC JV; operating lease right-of-use assets; and other assets. |
![]() | 12 |
Reconciliations |
In thousands |
Real Estate Revenue |
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Senior housing triple-net | $ | 63,602 | $ | 58,892 | $ | 49,866 | $ | 48,018 | $ | 42,665 | |||||||||
SHOP | 127,909 | 126,181 | 177,001 | 212,275 | 209,714 | ||||||||||||||
Life science | 96,371 | 94,473 | 107,596 | 118,561 | 120,155 | ||||||||||||||
Medical office(1) | 140,015 | 142,195 | 141,927 | 143,639 | 143,769 | ||||||||||||||
Other(1) | 12,664 | 12,700 | 12,763 | 12,737 | 12,412 | ||||||||||||||
Real Estate Revenue | $ | 440,561 | $ | 434,441 | $ | 489,153 | $ | 535,230 | $ | 528,715 | |||||||||
Senior housing triple-net | 2,436 | 435 | 4,793 | (1,551 | ) | (2,201 | ) | ||||||||||||
SHOP | 41 | 968 | 1,128 | 957 | 258 | ||||||||||||||
Life science | (2,178 | ) | (2,491 | ) | (7,627 | ) | (7,080 | ) | (4,975 | ) | |||||||||
Medical office(1) | (2,506 | ) | (2,710 | ) | (2,143 | ) | (2,509 | ) | (2,267 | ) | |||||||||
Other(1) | 194 | 194 | 219 | 469 | 461 | ||||||||||||||
Non-cash adjustments to Real Estate Revenues | $ | (2,013 | ) | $ | (3,604 | ) | $ | (3,630 | ) | $ | (9,714 | ) | $ | (8,724 | ) | ||||
Senior housing triple-net | 66,038 | 59,328 | 54,659 | 46,467 | 40,464 | ||||||||||||||
SHOP | 127,950 | 127,149 | 178,129 | 213,232 | 209,972 | ||||||||||||||
Life science | 94,193 | 91,982 | 99,969 | 111,481 | 115,180 | ||||||||||||||
Medical office(1) | 137,509 | 139,485 | 139,784 | 141,130 | 141,502 | ||||||||||||||
Other(1) | 12,858 | 12,895 | 12,982 | 13,206 | 12,873 | ||||||||||||||
Cash Real Estate Revenues | $ | 438,548 | $ | 430,839 | $ | 485,523 | $ | 525,516 | $ | 519,991 | |||||||||
Senior housing triple-net | (44,042 | ) | (37,331 | ) | (32,369 | ) | (24,165 | ) | (18,023 | ) | |||||||||
SHOP | (87,800 | ) | (85,719 | ) | (136,605 | ) | (171,454 | ) | (168,715 | ) | |||||||||
Life science | (16,455 | ) | (14,277 | ) | (20,255 | ) | (29,650 | ) | (33,038 | ) | |||||||||
Medical office(1) | (10,529 | ) | (10,133 | ) | (10,040 | ) | (9,683 | ) | (9,732 | ) | |||||||||
Other(1) | (484 | ) | (463 | ) | (479 | ) | (477 | ) | (92 | ) | |||||||||
Non-SPP Cash Real Estate Revenues | $ | (159,310 | ) | $ | (147,923 | ) | $ | (199,748 | ) | $ | (235,429 | ) | $ | (229,600 | ) | ||||
Senior housing triple-net | 21,996 | 21,997 | 22,290 | 22,302 | 22,441 | ||||||||||||||
SHOP | 40,150 | 41,430 | 41,524 | 41,778 | 41,257 | ||||||||||||||
Life science | 77,738 | 77,705 | 79,714 | 81,831 | 82,142 | ||||||||||||||
Medical office(1) | 126,980 | 129,352 | 129,744 | 131,447 | 131,770 | ||||||||||||||
Other(1) | 12,374 | 12,432 | 12,503 | 12,729 | 12,781 | ||||||||||||||
Cash Real Estate Revenues - SPP | $ | 279,238 | $ | 282,916 | $ | 285,775 | $ | 290,087 | $ | 290,391 | |||||||||
(1) | During the quarter ended March 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior period segment information has been recast to conform to the current period presentation. |
![]() | 13 |
Reconciliations |
In thousands |
Operating Expenses |
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Senior housing triple-net | $ | 941 | $ | 993 | $ | 866 | $ | 865 | $ | 1,842 | |||||||||
SHOP | 104,617 | 96,948 | 137,460 | 166,201 | 165,104 | ||||||||||||||
Life science | 23,534 | 21,992 | 25,480 | 29,520 | 30,480 | ||||||||||||||
Medical office(1) | 48,219 | 48,987 | 50,176 | 51,472 | 50,903 | ||||||||||||||
Other(1) | 102 | 7 | 11 | 11 | 53 | ||||||||||||||
Operating expenses | $ | 177,413 | $ | 168,927 | $ | 213,993 | $ | 248,069 | $ | 248,382 | |||||||||
Senior housing triple-net | (14 | ) | (129 | ) | (14 | ) | (14 | ) | (1,093 | ) | |||||||||
SHOP | (3,189 | ) | (184 | ) | 287 | 218 | 119 | ||||||||||||
Life science | (13 | ) | (13 | ) | (13 | ) | (13 | ) | (13 | ) | |||||||||
Medical office(1) | (945 | ) | (939 | ) | (940 | ) | (941 | ) | (932 | ) | |||||||||
Other(1) | — | 1 | — | — | 1 | ||||||||||||||
Non-cash adjustments to operating expenses | $ | (4,161 | ) | $ | (1,264 | ) | $ | (680 | ) | $ | (750 | ) | $ | (1,918 | ) | ||||
Senior housing triple-net | 927 | 864 | 852 | 851 | 749 | ||||||||||||||
SHOP | 101,428 | 96,764 | 137,747 | 166,419 | 165,223 | ||||||||||||||
Life science | 23,521 | 21,979 | 25,467 | 29,507 | 30,467 | ||||||||||||||
Medical office(1) | 47,274 | 48,048 | 49,236 | 50,531 | 49,971 | ||||||||||||||
Other(1) | 102 | 8 | 11 | 11 | 54 | ||||||||||||||
Cash Operating Expenses | $ | 173,252 | $ | 167,663 | $ | 213,313 | $ | 247,319 | $ | 246,464 | |||||||||
Senior housing triple-net | (892 | ) | (834 | ) | (822 | ) | (820 | ) | (725 | ) | |||||||||
SHOP | (71,273 | ) | (66,516 | ) | (107,202 | ) | (135,608 | ) | (134,556 | ) | |||||||||
Life science | (4,763 | ) | (4,453 | ) | (6,252 | ) | (9,648 | ) | (10,436 | ) | |||||||||
Medical office(1) | (4,456 | ) | (4,518 | ) | (4,841 | ) | (4,783 | ) | (4,669 | ) | |||||||||
Other(1) | (93 | ) | (3 | ) | (6 | ) | (6 | ) | 26 | ||||||||||
Non-SPP operating expenses | $ | (81,477 | ) | $ | (76,324 | ) | $ | (119,123 | ) | $ | (150,865 | ) | $ | (150,360 | ) | ||||
Senior housing triple-net | 35 | 30 | 30 | 31 | 24 | ||||||||||||||
SHOP | 30,155 | 30,248 | 30,545 | 30,811 | 30,667 | ||||||||||||||
Life science | 18,758 | 17,526 | 19,215 | 19,859 | 20,031 | ||||||||||||||
Medical office(1) | 42,818 | 43,530 | 44,395 | 45,748 | 45,302 | ||||||||||||||
Other(1) | 9 | 5 | 5 | 5 | 80 | ||||||||||||||
Cash Operating Expenses - SPP | $ | 91,775 | $ | 91,339 | $ | 94,190 | $ | 96,454 | $ | 96,104 | |||||||||
(1) | During the quarter ended March 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior period segment information has been recast to conform to the current period presentation. |
![]() | 14 |
Reconciliations |
In thousands |
Total Real Estate Revenue | Total Operating Expenses | |
Year Ended December 31, 2019 | Year Ended December 31, 2019 | |||||||
Senior housing triple-net | $ | 199,441 | Senior housing triple-net | $ | 4,565 | |||
SHOP | 725,171 | SHOP | 565,713 | |||||
Life science | 440,784 | Life science | 107,472 | |||||
Medical office | 571,530 | Medical office | 201,538 | |||||
Other | 50,613 | Other | 82 | |||||
Real Estate Revenue | $ | 1,987,539 | Operating expenses | $ | 879,370 | |||
Senior housing triple-net | 1,476 | Senior housing triple-net | (1,249 | ) | ||||
SHOP | 3,311 | SHOP | 439 | |||||
Life science | (22,172 | ) | Life science | (52 | ) | |||
Medical office | (9,628 | ) | Medical office | (3,751 | ) | |||
Other | 1,342 | Other | — | |||||
Non-cash adjustments to Real Estate Revenues | $ | (25,671 | ) | Non-cash adjustments to operating expenses | $ | (4,613 | ) | |
Senior housing triple-net | 200,917 | Senior housing triple-net | 3,316 | |||||
SHOP | 728,482 | SHOP | 566,152 | |||||
Life science | 418,612 | Life science | 107,420 | |||||
Medical office | 561,902 | Medical office | 197,787 | |||||
Other | 51,955 | Other | 82 | |||||
Cash Real Estate Revenues | $ | 1,961,868 | Cash Operating Expenses | $ | 874,757 | |||
Senior housing triple-net | (111,887 | ) | Senior housing triple-net | (3,202 | ) | |||
SHOP | (608,486 | ) | SHOP | (478,515 | ) | |||
Life science | (127,212 | ) | Life science | (38,050 | ) | |||
Medical office | (90,582 | ) | Medical office | (37,308 | ) | |||
Other | (1,509 | ) | Other | 13 | ||||
Non-SPP Cash Real Estate Revenues(1) | $ | (939,676 | ) | Non-SPP operating expenses(2) | $ | (557,062 | ) | |
Senior housing triple-net | 89,030 | Senior housing triple-net | 114 | |||||
SHOP | 119,996 | SHOP | 87,637 | |||||
Life science | 291,400 | Life science | 69,370 | |||||
Medical office | 471,320 | Medical office | 160,479 | |||||
Other | 50,446 | Other | 95 | |||||
Cash Real Estate Revenues - SPP(1) | $ | 1,022,192 | Cash Operating Expenses - SPP(2) | $ | 317,695 | |||
(1) | The property count used for Non-SPP Cash Real Estate Revenues and Cash Real Estate Revenues - SPP differed for the three and twelve months ended December 31, 2019. |
(2) | The property count used for Non-SPP operating expense and Cash Operating Expenses - SPP differed for the three and twelve months ended December 31, 2019. |
![]() | 15 |
Reconciliations |
In thousands |
Total Real Estate Revenue | Total Operating Expenses | |
Year Ended December 31, 2018 | Year Ended December 31, 2018 | |||||||
Senior housing triple-net | $ | 276,091 | Senior housing triple-net | $ | 3,618 | |||
SHOP | 547,976 | SHOP | 414,312 | |||||
Life science | 395,064 | Life science | 91,742 | |||||
Medical office(1) | 547,375 | Medical office(1) | 195,100 | |||||
Other(1) | 69,777 | Other(1) | 266 | |||||
Real Estate Revenue | $ | 1,836,283 | Operating expenses | $ | 705,038 | |||
Senior housing triple-net | 2,120 | Senior housing triple-net | (7 | ) | ||||
SHOP | (3,193 | ) | SHOP | (6,068 | ) | |||
Life science | (9,652 | ) | Life science | (63 | ) | |||
Medical office(1) | (10,077 | ) | Medical office(1) | (3,387 | ) | |||
Other(1) | (627 | ) | Other(1) | — | ||||
Non-cash adjustments to Real Estate Revenues | $ | (21,429 | ) | Non-cash adjustments to operating expenses | $ | (9,525 | ) | |
Senior housing triple-net | 278,211 | Senior housing triple-net | 3,611 | |||||
SHOP | 544,783 | SHOP | 408,244 | |||||
Life science | 385,412 | Life science | 91,679 | |||||
Medical office(1) | 537,298 | Medical office(1) | 191,713 | |||||
Other(1) | 69,150 | Other(1) | 266 | |||||
Cash Real Estate Revenues | $ | 1,814,854 | Cash Operating Expenses | $ | 695,513 | |||
Senior housing triple-net | (191,287 | ) | Senior housing triple-net | (3,486 | ) | |||
SHOP | (427,973 | ) | SHOP | (324,121 | ) | |||
Life science | (111,314 | ) | Life science | (26,725 | ) | |||
Medical office(1) | (78,227 | ) | Medical office(1) | (34,383 | ) | |||
Other(1) | (20,069 | ) | Other(1) | (242 | ) | |||
Non-SPP Cash Real Estate Revenues(2) | $ | (828,870 | ) | Non-SPP operating expenses(3) | $ | (388,957 | ) | |
Senior housing triple-net | 86,924 | Senior housing triple-net | 125 | |||||
SHOP | 116,810 | SHOP | 84,123 | |||||
Life science | 274,098 | Life science | 64,954 | |||||
Medical office(1) | 459,071 | Medical office(1) | 157,330 | |||||
Other(1) | 49,081 | Other(1) | 24 | |||||
Cash Real Estate Revenues - SPP(2) | $ | 985,984 | Cash Operating Expenses - SPP(3) | $ | 306,556 | |||
(1) | During the year ended December 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior year segment information has been recast to conform to the current year presentation. |
(2) | The property count used for Non-SPP Cash Real Estate Revenues and Cash Real Estate Revenues - SPP differed for the three and twelve months ended December 31, 2018. |
(3) | The property count used for Non-SPP operating expense and Cash Operating Expenses - SPP differed for the three and twelve months ended December 31, 2018. |
![]() | 16 |
Reconciliations |
In thousands |
EBITDAre and Adjusted EBITDAre |
Three Months Ended December 31, 2019 | Twelve Months Ended December 31, 2019 | ||||||
Net income (loss) | $ | 47,359 | $ | 60,061 | |||
Interest expense | 58,120 | 225,619 | |||||
Income tax expense (benefit) | (5,679 | ) | (17,262 | ) | |||
Depreciation and amortization | 190,798 | 659,989 | |||||
Other depreciation and amortization | 2,166 | 9,158 | |||||
Loss (gain) on sales of real estate | (4,193 | ) | (22,900 | ) | |||
Loss (gain) upon change of control | (155,225 | ) | (168,023 | ) | |||
Impairments (recoveries) of depreciable real estate | 110,284 | 215,790 | |||||
Share of unconsolidated JV: | |||||||
Interest expense | 3,289 | 14,825 | |||||
Income tax expense (benefit) | 183 | 674 | |||||
Depreciation and amortization | 15,151 | 60,303 | |||||
Impairments (recoveries) of depreciable real estate | — | 5,527 | |||||
Gain on sale of real estate from unconsolidated JVs | (2,118 | ) | (2,118 | ) | |||
Other JV adjustments | (400 | ) | (2,010 | ) | |||
EBITDAre | $ | 259,735 | $ | 1,039,633 | |||
Transaction-related items | 1,688 | 15,347 | |||||
Other impairments (recoveries) and losses (gains) | — | 10,147 | |||||
Severance and related charges | — | 5,063 | |||||
Loss on debt extinguishments | 22,213 | 58,364 | |||||
Litigation costs (recoveries) | 29 | (520 | ) | ||||
Casualty-related charges (recoveries) | 700 | (3,706 | ) | ||||
Amortization of deferred compensation | 3,177 | 14,790 | |||||
Foreign currency remeasurement losses (gains) | 100 | (250 | ) | ||||
CCRC entrance fees(1) | 4,785 | 18,856 | |||||
Adjusted EBITDAre | $ | 292,427 | $ | 1,157,724 | |||
Adjusted Fixed Charge Coverage |
Three Months Ended December 31, 2019 | Twelve Months Ended December 31, 2019 | ||||||
Interest expense | $ | 58,120 | $ | 225,619 | |||
Capitalized interest | 7,630 | 30,109 | |||||
Share of unconsolidated JV interest expense and capitalized interest | 3,555 | 15,686 | |||||
Fixed Charges | $ | 69,305 | $ | 271,414 | |||
Adjusted Fixed Charge Coverage | 4.2x | 4.3x | |||||
(1) | Represents our 49% share of our CCRC JV's non-refundable entrance fees collected in excess of amortization. |
![]() | 17 |
Reconciliations |
In thousands |
Enterprise Debt and Net Debt |
December 31, 2019 | |||
Bank line of credit and commercial paper(1) | $ | 93,000 | |
Term loan | 248,942 | ||
Senior unsecured notes | 5,647,993 | ||
Mortgage debt(2) | 309,196 | ||
Other debt | 84,771 | ||
Consolidated Debt | $ | 6,383,902 | |
Share of unconsolidated JV mortgage debt | 184,218 | ||
Share of unconsolidated JV other debt | 164,543 | ||
Enterprise Debt | $ | 6,732,663 | |
Cash and cash equivalents | (144,232 | ) | |
Share of unconsolidated JV cash and cash equivalents | (31,520 | ) | |
Net Debt | $ | 6,556,911 | |
Financial Leverage |
December 31, 2019 | |||
Enterprise Debt | $ | 6,732,663 | |
Enterprise Gross Assets | 18,143,835 | ||
Financial Leverage | 37.1% | ||
Secured Debt Ratio |
December 31, 2019 | |||
Mortgage debt | $ | 309,196 | |
Share of unconsolidated JV mortgage debt | 184,218 | ||
Enterprise Secured Debt | $ | 493,414 | |
Enterprise Gross Assets | 18,143,835 | ||
Secured Debt Ratio | 2.7% | ||
Net Debt to Adjusted EBITDAre |
Three Months Ended December 31, 2019 | Twelve Months Ended December 31, 2019 | ||||||
Net Debt | $ | 6,556,911 | $ | 6,556,911 | |||
Adjusted EBITDAre | 1,169,708 | (3) | 1,157,724 | ||||
Net Debt to Adjusted EBITDAre | 5.6x | 5.7x | |||||
(1) | Includes $93 million of commercial paper at December 31, 2019. |
(2) | Includes mortgage debt of $32.3 million on assets held for sale that matures in 2026, 2028 and 2044. |
(3) | Represents the current quarter Adjusted EBIDTAre multiplied by a factor of four. |
![]() | 18 |
Reconciliations |
In thousands |
Segment Cash NOI, Portfolio Income, and SPP |
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | 834,383 | $ | 64,990 | $ | (9,980 | ) | $ | (42,308 | ) | $ | 47,359 | |||||||
Interest income | (1,358 | ) | (1,713 | ) | (2,414 | ) | (2,741 | ) | (2,976 | ) | |||||||||
Interest expense | 54,717 | 49,327 | 56,942 | 61,230 | 58,120 | ||||||||||||||
Depreciation and amortization | 130,759 | 131,951 | 165,296 | 171,944 | 190,798 | ||||||||||||||
General and administrative | 21,510 | 21,355 | 27,120 | 22,970 | 21,521 | ||||||||||||||
Transaction costs | 1,684 | 4,518 | 1,337 | 1,319 | 1,569 | ||||||||||||||
Loss (gain) on sales of real estate, net | (763,774 | ) | (8,044 | ) | (11,448 | ) | 784 | (4,193 | ) | ||||||||||
Impairments (recoveries), net | 36,080 | 8,858 | 68,538 | 38,257 | 110,284 | ||||||||||||||
Other expense (income), net | (50,333 | ) | (3,133 | ) | (21,008 | ) | (693 | ) | (157,296 | ) | |||||||||
Loss on debt extinguishments | 263 | — | 1,135 | 35,017 | 22,213 | ||||||||||||||
Income tax expense (benefit) | (2,935 | ) | (3,458 | ) | (1,864 | ) | (6,261 | ) | (5,679 | ) | |||||||||
Equity loss (income) from unconsolidated JVs | 2,152 | 863 | 1,506 | 7,643 | (1,387 | ) | |||||||||||||
NOI | $ | 263,148 | $ | 265,514 | $ | 275,160 | $ | 287,161 | $ | 280,333 | |||||||||
Adjustment to NOI | 2,148 | (2,338 | ) | (2,950 | ) | (8,963 | ) | (6,805 | ) | ||||||||||
Cash NOI | $ | 265,296 | $ | 263,176 | $ | 272,210 | $ | 278,198 | $ | 273,528 | |||||||||
Interest income | 1,358 | 1,713 | 2,414 | 2,741 | 2,976 | ||||||||||||||
Share of unconsolidated JVs | 21,466 | 21,400 | 22,233 | 21,569 | 20,765 | ||||||||||||||
Portfolio Income | $ | 288,120 | $ | 286,289 | $ | 296,857 | $ | 302,508 | $ | 297,269 | |||||||||
Interest income | (1,358 | ) | (1,713 | ) | (2,414 | ) | (2,741 | ) | (2,976 | ) | |||||||||
Share of unconsolidated JVs | (21,466 | ) | (21,400 | ) | (22,233 | ) | (21,569 | ) | (20,765 | ) | |||||||||
Adjustment to NOI | (2,148 | ) | 2,338 | 2,950 | 8,963 | 6,805 | |||||||||||||
Non-SPP NOI | (74,992 | ) | (72,080 | ) | (81,581 | ) | (90,012 | ) | (84,387 | ) | |||||||||
SPP NOI | $ | 188,156 | $ | 193,434 | $ | 193,579 | $ | 197,149 | $ | 195,946 | |||||||||
Non-cash adjustment to SPP NOI | (693 | ) | (1,857 | ) | (1,994 | ) | (3,516 | ) | (1,659 | ) | |||||||||
SPP cash NOI | $ | 187,463 | $ | 191,577 | $ | 191,585 | $ | 193,633 | $ | 194,287 | |||||||||
![]() | 19 |
Reconciliations |
In thousands |
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | 67,827 | $ | 44,184 | $ | 17,616 | $ | 26,839 | $ | 9,570 | |||||||||
Interest expense | 598 | 589 | 206 | 106 | 102 | ||||||||||||||
Depreciation and amortization | 17,564 | 16,683 | 15,693 | 12,778 | 10,207 | ||||||||||||||
Impairments (recoveries), net | — | — | 15,485 | 7,430 | 20,944 | ||||||||||||||
Loss (gain) on sales of real estate, net | (23,328 | ) | (3,557 | ) | — | — | — | ||||||||||||
NOI | $ | 62,661 | $ | 57,899 | $ | 49,000 | $ | 47,153 | $ | 40,823 | |||||||||
Adjustment to NOI | 2,450 | 564 | 4,807 | (1,537 | ) | (1,108 | ) | ||||||||||||
Cash NOI | $ | 65,111 | $ | 58,463 | $ | 53,807 | $ | 45,616 | $ | 39,715 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Portfolio Income | $ | 65,111 | $ | 58,463 | $ | 53,807 | $ | 45,616 | $ | 39,715 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Adjustment to NOI | (2,450 | ) | (564 | ) | (4,807 | ) | 1,537 | 1,108 | |||||||||||
Non-SPP NOI | (41,169 | ) | (36,599 | ) | (27,212 | ) | (23,689 | ) | (17,333 | ) | |||||||||
SPP NOI | $ | 21,492 | $ | 21,300 | $ | 21,788 | $ | 23,464 | $ | 23,490 | |||||||||
Non-cash adjustment to SPP NOI | 469 | 667 | 472 | (1,193 | ) | (1,073 | ) | ||||||||||||
SPP cash NOI | $ | 21,961 | $ | 21,967 | $ | 22,260 | $ | 22,271 | $ | 22,417 | |||||||||
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | (19,145 | ) | $ | 8,971 | $ | (62,299 | ) | $ | (40,170 | ) | $ | 46,354 | ||||||
Interest expense | 659 | 663 | 1,326 | 2,637 | 2,893 | ||||||||||||||
Depreciation and amortization | 23,609 | 24,086 | 52,242 | 58,152 | 80,106 | ||||||||||||||
Impairments (recoveries), net | 32,802 | — | 52,963 | 24,721 | 86,684 | ||||||||||||||
Loss (gain) on sales of real estate, net | (14,633 | ) | (4,487 | ) | (4,691 | ) | 734 | (10,541 | ) | ||||||||||
Other expense (income), net | — | — | — | — | (160,886 | ) | |||||||||||||
NOI | $ | 23,292 | $ | 29,233 | $ | 39,541 | $ | 46,074 | $ | 44,610 | |||||||||
Adjustment to NOI | 3,230 | 1,152 | 841 | 740 | 139 | ||||||||||||||
Cash NOI | $ | 26,522 | $ | 30,385 | $ | 40,382 | $ | 46,814 | $ | 44,749 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Portfolio Income | $ | 26,522 | $ | 30,385 | $ | 40,382 | $ | 46,814 | $ | 44,749 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Adjustment to NOI | (3,230 | ) | (1,152 | ) | (841 | ) | (740 | ) | (139 | ) | |||||||||
Non-SPP NOI | (14,887 | ) | (18,291 | ) | (28,720 | ) | (35,172 | ) | (34,014 | ) | |||||||||
SPP NOI | $ | 8,405 | $ | 10,942 | $ | 10,821 | $ | 10,902 | $ | 10,596 | |||||||||
Non-cash adjustment to SPP NOI | 1,590 | 240 | 158 | 65 | (6 | ) | |||||||||||||
SPP cash NOI | $ | 9,995 | $ | 11,182 | $ | 10,979 | $ | 10,967 | $ | 10,590 | |||||||||
![]() | 20 |
Reconciliations |
In thousands |
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | 763,666 | $ | 36,162 | $ | 44,431 | $ | 43,858 | $ | 43,975 | |||||||||
Interest expense | 76 | 73 | 70 | 68 | 66 | ||||||||||||||
Depreciation and amortization | 34,699 | 36,246 | 41,431 | 45,028 | 45,634 | ||||||||||||||
Impairments (recoveries), net | — | — | — | — | — | ||||||||||||||
Loss (gain) on sales of real estate, net | (725,604 | ) | — | (3,816 | ) | 87 | — | ||||||||||||
NOI | $ | 72,837 | $ | 72,481 | $ | 82,116 | $ | 89,041 | $ | 89,675 | |||||||||
Adjustment to NOI | (2,165 | ) | (2,478 | ) | (7,614 | ) | (7,067 | ) | (4,961 | ) | |||||||||
Cash NOI | $ | 70,672 | $ | 70,003 | $ | 74,502 | $ | 81,974 | $ | 84,714 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Portfolio Income | $ | 70,672 | $ | 70,003 | $ | 74,502 | $ | 81,974 | $ | 84,714 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Adjustment to NOI | 2,165 | 2,478 | 7,614 | 7,067 | 4,961 | ||||||||||||||
Non-SPP NOI | (12,496 | ) | (11,146 | ) | (19,969 | ) | (25,698 | ) | (27,746 | ) | |||||||||
SPP NOI | $ | 60,341 | $ | 61,335 | $ | 62,147 | $ | 63,343 | $ | 61,929 | |||||||||
Non-cash adjustment to SPP NOI | (1,361 | ) | (1,156 | ) | (1,648 | ) | (1,371 | ) | 182 | ||||||||||
SPP cash NOI | $ | 58,980 | $ | 60,179 | $ | 60,499 | $ | 61,972 | $ | 62,111 | |||||||||
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | 39,042 | $ | 31,138 | $ | 40,397 | $ | 32,171 | $ | 37,045 | |||||||||
Interest expense | 118 | 111 | 109 | 108 | 105 | ||||||||||||||
Depreciation and amortization | 53,163 | 53,101 | 54,096 | 54,152 | 53,323 | ||||||||||||||
Impairments (recoveries), net | — | 8,858 | 90 | 5,729 | 2,656 | ||||||||||||||
Loss (gain) on sales of real estate, net | (527 | ) | — | (2,941 | ) | 7 | (263 | ) | |||||||||||
NOI | $ | 91,796 | $ | 93,208 | $ | 91,751 | $ | 92,167 | $ | 92,866 | |||||||||
Adjustment to NOI | (1,561 | ) | (1,771 | ) | (1,203 | ) | (1,568 | ) | (1,335 | ) | |||||||||
Cash NOI | $ | 90,235 | $ | 91,437 | $ | 90,548 | $ | 90,599 | $ | 91,531 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Portfolio Income | $ | 90,235 | $ | 91,437 | $ | 90,548 | $ | 90,599 | $ | 91,531 | |||||||||
Interest income | — | — | — | — | — | ||||||||||||||
Share of unconsolidated JVs | — | — | — | — | — | ||||||||||||||
Adjustment to NOI | 1,561 | 1,771 | 1,203 | 1,568 | 1,335 | ||||||||||||||
Non-SPP NOI | (6,048 | ) | (5,584 | ) | (5,209 | ) | (4,982 | ) | (5,174 | ) | |||||||||
SPP NOI | $ | 85,748 | $ | 87,624 | $ | 86,542 | $ | 87,185 | $ | 87,692 | |||||||||
Non-cash adjustment to SPP NOI | (1,586 | ) | (1,802 | ) | (1,193 | ) | (1,486 | ) | (1,224 | ) | |||||||||
SPP cash NOI | $ | 84,162 | $ | 85,822 | $ | 85,349 | $ | 85,699 | $ | 86,468 | |||||||||
![]() | 21 |
Reconciliations |
In thousands |
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | 56,619 | $ | 11,708 | $ | 24,643 | $ | 6,637 | $ | 2,918 | |||||||||
Interest income | (1,358 | ) | (1,713 | ) | (2,414 | ) | (2,741 | ) | (2,976 | ) | |||||||||
Interest expense | — | — | — | — | — | ||||||||||||||
Depreciation and amortization | 1,724 | 1,835 | 1,834 | 1,834 | 1,528 | ||||||||||||||
Impairments (recoveries), net | 3,278 | — | — | 377 | — | ||||||||||||||
Loss (gain) on sales of real estate, net | 318 | — | — | (44 | ) | 6,611 | |||||||||||||
Other expense (income), net | (50,171 | ) | — | (12,817 | ) | (980 | ) | 5,665 | |||||||||||
Equity loss (income) from unconsolidated JVs | 2,152 | 863 | 1,506 | 7,643 | (1,387 | ) | |||||||||||||
NOI | $ | 12,562 | $ | 12,693 | $ | 12,752 | $ | 12,726 | $ | 12,359 | |||||||||
Adjustment to NOI | 194 | 195 | 219 | 469 | 460 | ||||||||||||||
Cash NOI | $ | 12,756 | $ | 12,888 | $ | 12,971 | $ | 13,195 | $ | 12,819 | |||||||||
Interest income | 1,358 | 1,713 | 2,414 | 2,741 | 2,976 | ||||||||||||||
Share of unconsolidated JVs | 21,466 | 21,400 | 22,233 | 21,569 | 20,765 | ||||||||||||||
Portfolio Income | $ | 35,580 | $ | 36,001 | $ | 37,618 | $ | 37,505 | $ | 36,560 | |||||||||
Interest income | (1,358 | ) | (1,713 | ) | (2,414 | ) | (2,741 | ) | (2,976 | ) | |||||||||
Share of unconsolidated JVs | (21,466 | ) | (21,400 | ) | (22,233 | ) | (21,569 | ) | (20,765 | ) | |||||||||
Adjustment to NOI | (194 | ) | (195 | ) | (219 | ) | (469 | ) | (460 | ) | |||||||||
Non-SPP NOI | (392 | ) | (460 | ) | (471 | ) | (471 | ) | (120 | ) | |||||||||
SPP NOI | $ | 12,170 | $ | 12,233 | $ | 12,281 | $ | 12,255 | $ | 12,239 | |||||||||
Non-cash adjustment to SPP NOI | 195 | 194 | 217 | 469 | 462 | ||||||||||||||
SPP cash NOI | $ | 12,365 | $ | 12,427 | $ | 12,498 | $ | 12,724 | $ | 12,701 | |||||||||
Three Months Ended | |||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | |||||||||||||||
Net income (loss) | $ | (73,626 | ) | $ | (67,173 | ) | $ | (74,768 | ) | $ | (111,643 | ) | $ | (92,503 | ) | ||||
Interest expense | 53,266 | 47,891 | 55,231 | 58,311 | 54,954 | ||||||||||||||
General and administrative | 21,510 | 21,355 | 27,120 | 22,970 | 21,521 | ||||||||||||||
Transaction costs | 1,684 | 4,518 | 1,337 | 1,319 | 1,569 | ||||||||||||||
Other expense (income), net | (162 | ) | (3,133 | ) | (8,191 | ) | 287 | (2,075 | ) | ||||||||||
Loss on debt extinguishments | 263 | — | 1,135 | 35,017 | 22,213 | ||||||||||||||
Income tax expense (benefit) | (2,935 | ) | (3,458 | ) | (1,864 | ) | (6,261 | ) | (5,679 | ) | |||||||||
NOI | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||
(1) | During the quarter ended March 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior period segment information has been recast to conform to the current period presentation. |
![]() | 22 |
Reconciliations |
In thousands |
Segment Cash NOI Same Property Performance |
Senior Housing Triple-Net | SHOP | Life Science | Medical Office(1) | Other(1) | Corporate Non-segment | Total | ||||||||||||||||||||||
Net income (loss) | $ | 98,210 | $ | (46,750 | ) | $ | 168,347 | $ | 140,696 | $ | 45,649 | $ | (346,091 | ) | $ | 60,061 | ||||||||||||
Interest income | — | — | — | — | (9,844 | ) | — | (9,844 | ) | |||||||||||||||||||
Interest expense | 1,003 | 7,519 | 277 | 434 | — | 216,386 | 225,619 | |||||||||||||||||||||
Depreciation and amortization | 55,361 | 214,590 | 168,339 | 214,669 | 7,030 | — | 659,989 | |||||||||||||||||||||
General and administrative | — | — | — | — | — | 92,966 | 92,966 | |||||||||||||||||||||
Transaction costs | — | — | — | — | — | 8,743 | 8,743 | |||||||||||||||||||||
Loss (gain) on sales of real estate, net | (3,557 | ) | (19,384 | ) | (3,651 | ) | (3,139 | ) | 6,831 | — | (22,900 | ) | ||||||||||||||||
Impairments (recoveries), net | 43,859 | 164,369 | — | 17,332 | 377 | — | 225,937 | |||||||||||||||||||||
Other expense (income), net | — | (160,886 | ) | — | — | (8,137 | ) | (13,106 | ) | (182,129 | ) | |||||||||||||||||
Loss on debt extinguishments | — | — | — | — | — | 58,364 | 58,364 | |||||||||||||||||||||
Income tax expense (benefit) | — | — | — | — | — | (17,262 | ) | (17,262 | ) | |||||||||||||||||||
Equity loss (income) from unconsolidated JVs | — | — | — | — | 8,625 | — | 8,625 | |||||||||||||||||||||
NOI | $ | 194,876 | $ | 159,458 | $ | 333,312 | $ | 369,992 | $ | 50,531 | $ | — | $ | 1,108,169 | ||||||||||||||
Adjustment to NOI | 2,725 | 2,872 | (22,120 | ) | (5,877 | ) | 1,342 | — | (21,058 | ) | ||||||||||||||||||
Cash NOI | $ | 197,601 | $ | 162,330 | $ | 311,192 | $ | 364,115 | $ | 51,873 | $ | — | $ | 1,087,111 | ||||||||||||||
Interest income | — | — | — | — | 9,844 | — | 9,844 | |||||||||||||||||||||
Share of unconsolidated JVs | — | — | — | — | 85,967 | — | 85,967 | |||||||||||||||||||||
Portfolio Income | $ | 197,601 | $ | 162,330 | $ | 311,192 | $ | 364,115 | $ | 147,684 | $ | — | $ | 1,182,922 | ||||||||||||||
Interest income | — | — | — | — | (9,844 | ) | — | (9,844 | ) | |||||||||||||||||||
Share of unconsolidated JVs | — | — | — | — | (85,967 | ) | — | (85,967 | ) | |||||||||||||||||||
Adjustment to NOI | (2,725 | ) | (2,872 | ) | 22,120 | 5,877 | (1,342 | ) | — | 21,058 | ||||||||||||||||||
Non-SPP NOI | (104,834 | ) | (127,221 | ) | (109,334 | ) | (54,708 | ) | (1,523 | ) | — | (397,620 | ) | |||||||||||||||
SPP NOI | $ | 90,042 | $ | 32,237 | $ | 223,978 | $ | 315,284 | $ | 49,008 | $ | — | $ | 710,549 | ||||||||||||||
Non-cash adjustment to SPP NOI | (1,126 | ) | 122 | (1,948 | ) | (4,443 | ) | 1,343 | — | (6,052 | ) | |||||||||||||||||
SPP cash NOI | $ | 88,916 | $ | 32,359 | $ | 222,030 | $ | 310,841 | $ | 50,351 | $ | — | $ | 704,497 | ||||||||||||||
![]() | 23 |
Reconciliations |
In thousands |
Senior Housing Triple-Net | SHOP | Life Science | Medical Office(1) | Other(1) | Corporate Non-segment | Total | ||||||||||||||||||||||
Net income (loss) | $ | 191,105 | $ | 76,168 | $ | 961,071 | $ | 155,799 | $ | 78,357 | $ | (389,026 | ) | $ | 1,073,474 | |||||||||||||
Interest income | — | — | — | — | (10,406 | ) | — | (10,406 | ) | |||||||||||||||||||
Interest expense | 2,404 | 2,725 | 316 | 474 | 1,469 | 258,955 | 266,343 | |||||||||||||||||||||
Depreciation and amortization | 79,605 | 104,405 | 140,480 | 200,430 | 24,579 | — | 549,499 | |||||||||||||||||||||
General and administrative | — | — | — | — | — | 96,702 | 96,702 | |||||||||||||||||||||
Transaction costs | — | — | — | — | — | 10,772 | 10,772 | |||||||||||||||||||||
Loss (gain) on sales of real estate, net | (641 | ) | (93,977 | ) | (806,184 | ) | (4,428 | ) | (20,755 | ) | — | (925,985 | ) | |||||||||||||||
Impairments (recoveries), net | — | 44,343 | 7,639 | — | 3,278 | — | 55,260 | |||||||||||||||||||||
Other expense (income), net | — | — | — | — | (9,605 | ) | (3,711 | ) | (13,316 | ) | ||||||||||||||||||
Loss on debt extinguishments | — | — | — | — | — | 44,162 | 44,162 | |||||||||||||||||||||
Income tax expense (benefit) | — | — | — | — | — | (17,854 | ) | (17,854 | ) | |||||||||||||||||||
Equity loss (income) from unconsolidated JVs | — | — | — | — | 2,594 | — | 2,594 | |||||||||||||||||||||
NOI | $ | 272,473 | $ | 133,664 | $ | 303,322 | $ | 352,275 | $ | 69,511 | $ | — | $ | 1,131,245 | ||||||||||||||
Adjustment to NOI | 2,127 | 2,875 | (9,589 | ) | (6,690 | ) | (627 | ) | — | (11,904 | ) | |||||||||||||||||
Cash NOI | $ | 274,600 | $ | 136,539 | $ | 293,733 | $ | 345,585 | $ | 68,884 | $ | — | $ | 1,119,341 | ||||||||||||||
Interest income | — | — | — | — | 10,406 | — | 10,406 | |||||||||||||||||||||
Share of unconsolidated JVs | — | — | — | — | 64,906 | — | 64,906 | |||||||||||||||||||||
Portfolio Income | $ | 274,600 | $ | 136,539 | $ | 293,733 | $ | 345,585 | $ | 144,196 | $ | — | $ | 1,194,653 | ||||||||||||||
Interest income | — | — | — | — | (10,406 | ) | — | (10,406 | ) | |||||||||||||||||||
Share of unconsolidated JVs | — | — | — | — | (64,906 | ) | — | (64,906 | ) | |||||||||||||||||||
Adjustment to NOI | (2,127 | ) | (2,875 | ) | 9,589 | 6,690 | 627 | — | 11,904 | |||||||||||||||||||
Non-SPP NOI | (186,855 | ) | (102,813 | ) | (91,343 | ) | (44,854 | ) | (21,127 | ) | — | (446,992 | ) | |||||||||||||||
SPP NOI | $ | 85,618 | $ | 30,851 | $ | 211,979 | $ | 307,421 | $ | 48,384 | $ | — | $ | 684,253 | ||||||||||||||
Non-cash adjustment to SPP NOI | 1,180 | 1,835 | (2,835 | ) | (5,681 | ) | 673 | — | (4,828 | ) | ||||||||||||||||||
SPP cash NOI | $ | 86,798 | $ | 32,686 | $ | 209,144 | $ | 301,740 | $ | 49,057 | $ | — | $ | 679,425 | ||||||||||||||
(1) | During the year ended December 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior year segment information has been recast to conform to the current year presentation. |
![]() | 24 |
Reconciliations |
In thousands |
Pro forma Portfolio Income(1) | ||||
Three Months Ended December 31, 2019 | ||||||||||||||||||||||||
Senior Housing Triple-net | SHOP | Life Science | Medical Office | Other | Total | |||||||||||||||||||
Portfolio Income(2) | $ | 39,715 | $ | 44,749 | $ | 84,714 | $ | 91,531 | $ | 36,560 | $ | 297,269 | ||||||||||||
Pro forma Adjustments: | ||||||||||||||||||||||||
Senior housing asset sales and transitions(3) | (19,195 | ) | (2,461 | ) | — | — | 14,283 | (7,374 | ) | |||||||||||||||
Other pro forma adjustments(4) | — | — | 2,030 | (697 | ) | 622 | 1,955 | |||||||||||||||||
Pro forma Portfolio Income | $ | 20,519 | $ | 42,288 | $ | 86,743 | $ | 90,834 | $ | 51,465 | $ | 291,850 | ||||||||||||
(1) | Does not foot due to rounding and adjustments made to the Supplemental Report. |
(2) | See pages 19 to 22 of this document for a reconciliation of Portfolio Income to net income. |
(3) | Includes pro forma adjustments to reflect asset sales and asset transitions from senior housing triple-net to SHOP in connection with the Master Transactions and Cooperation Agreement with Brookdale Senior Living Inc., the Senior Housing Joint Venture, and certain other previously announced sales and transitions. |
(4) | Pro forma to reflect the sale of our U.K. holdings and certain previously announced sales. Pro forma Portfolio Income is further adjusted to reflect acquisitions, dispositions, and other operator transitions as if they occurred on the first day of the quarter. |
![]() | 25 |
Reconciliations |
In thousands, except per month data |
REVPOR SHOP(1) |
Three Months Ended | ||||||||||||||||||||
December 31, 2018 | March 31, 2019 | June 30, 2019 | September 30, 2019 | December 31, 2019 | ||||||||||||||||
REVPOR SHOP | ||||||||||||||||||||
Real Estate Revenues | $ | 127,909 | $ | 126,181 | $ | 177,001 | $ | 212,275 | $ | 209,714 | ||||||||||
Adjustments to real estate revenues | 41 | 968 | 1,128 | 957 | 258 | |||||||||||||||
Cash Real Estate Revenues | $ | 127,950 | $ | 127,149 | $ | 178,129 | $ | 213,232 | $ | 209,972 | ||||||||||
Other adjustments to REVPOR SHOP(2) | (28,998 | ) | (21,714 | ) | (31,002 | ) | (28,094 | ) | (76,517 | ) | ||||||||||
REVPOR SHOP revenues | $ | 98,952 | $ | 105,436 | $ | 147,127 | $ | 185,138 | $ | 133,455 | ||||||||||
Average occupied units/month | 7,745 | 7,664 | 9,955 | 11,579 | 7,304 | |||||||||||||||
REVPOR SHOP per month(3) | $ | 4,259 | $ | 4,586 | $ | 4,927 | $ | 5,330 | $ | 6,091 | ||||||||||
SPP REVPOR SHOP | ||||||||||||||||||||
REVPOR SHOP revenues | $ | 98,952 | $ | 105,436 | $ | 147,127 | $ | 185,138 | $ | 133,455 | ||||||||||
Change in reporting structure(4) | — | (7,935 | ) | (37,036 | ) | (65,453 | ) | (65,578 | ) | |||||||||||
Other non-SPP cash real estate revenues | (58,801 | ) | (56,070 | ) | (68,567 | ) | (77,907 | ) | (26,619 | ) | ||||||||||
SPP REVPOR SHOP revenues | $ | 40,150 | $ | 41,430 | $ | 41,524 | $ | 41,778 | $ | 41,257 | ||||||||||
SPP average occupied units/month | 2,889 | 2,882 | 2,902 | 2,947 | 2,942 | |||||||||||||||
SPP REVPOR SHOP per month(3) | $ | 4,633 | $ | 4,792 | $ | 4,769 | $ | 4,725 | $ | 4,675 | ||||||||||
(1) | Does not foot due to rounding and adjustments made to the Supplemental Report. |
(2) | Includes revenue for newly completed facilities under lease-up, facilities sold or held for sale, facilities acquired or transitioned to new operators during the relevant period, and assets in redevelopment. |
(3) | Represents the current quarter REVPOR divided by a factor of three. |
(4) | Represents revenues for assets that transitioned from senior housing triple-net to SHOP during the year-over-year comparison period. |
![]() | 26 |